Bradford Smith, MD
Internal Medicine · Baker, LANPI 1144271602
Payments from drug & device makers
Across 252 payments — averaging $16.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$741
- Novo Nordisk$533
- Abbott$406
- Pfizer$252
- Bayer$236
- AstraZeneca$226
- plus $2K from 31 others
What the payments were for
- Food & beverage$4,144100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 56 | $741 |
| Novo Nordisk | 34 | $533 |
| Abbott | 17 | $406 |
| Pfizer | 14 | $252 |
| Bayer | 13 | $236 |
| AstraZeneca(2 entities) | 13 | $226 |
| Boehringer Ingelheim | 14 | $222 |
| Johnson & Johnson | 12 | $171 |
| Amgen | 10 | $168 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $152 |
| GSK | 7 | $119 |
| Merck | 8 | $116 |
| AbbVie | 6 | $100 |
| Amarin Pharma, Inc. | 6 | $96 |
| Dexcom, Inc. | 3 | $72 |
| Teva Pharmaceuticals USA, Inc. | 3 | $51 |
| Xeris Pharmaceuticals, Inc. | 3 | $45 |
| Daiichi Sankyo Inc. | 2 | $44 |
| Ironshore Pharmaceuticals Inc. | 2 | $35 |
| Soleno Therapeutics, Inc. | 1 | $31 |
| Novartis | 2 | $30 |
| Acadia Pharmaceuticals Inc | 2 | $27 |
| Sanofi-aventis U.S. LLC | 1 | $25 |
| Organon | 1 | $24 |
| Hikma Pharmaceuticals USA | 1 | $23 |
| Dynavax Technologies Corporation | 1 | $22 |
| Azurity Pharmaceuticals, Inc. | 1 | $20 |
| Axsome Therapeutics, Inc. | 1 | $20 |
| Biogen | 1 | $20 |
| Adlon Therapeutics L.p. | 1 | $19 |
| Neos Therapeutics, LP | 1 | $18 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $15 |
| Currax Pharmaceuticals LLC | 1 | $14 |
| Supernus Pharmaceuticals, Inc. | 1 | $14 |
| Shire North American Group Inc | 1 | $13 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
| Esperion Therapeutics, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PROCLAIM$101
How this compares
$4,144 in reported general payments places this provider in the 80th percentile of 1,528 internal medicine providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 116 | $122,206 |
| TrulicityDulaglutide | 47 | $47,018 |
| JanuviaSitagliptin Phosphate | 54 | $46,433 |
| OzempicSemaglutide | 22 | $30,500 |
| EliquisApixaban | 34 | $23,914 |
| MounjaroTirzepatide | 23 | $23,748 |
| FarxigaDapagliflozin Propanediol | 18 | $16,219 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 28 | $15,266 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 17 | $13,264 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 67 | $12,883 |
| Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide | 194 | $3,984 |
| Atorvastatin Calcium | 481 | $3,900 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 79 | $2,016 |
| Rosuvastatin Calcium | 175 | $1,834 |
| Pantoprazole Sodium | 245 | $1,719 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $222 | $122,206116 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $741 | $70,76670 claims |
| MerckJanuvia | $116 | $46,43354 claims |
| Novo NordiskOzempic | $533 | $30,50022 claims |
| PfizerEliquis | $252 | $23,91434 claims |
| AstraZenecaFarxiga | $226 | $16,21918 claims |
| GSKTrelegy Ellipta | $119 | $13,26417 claims |
| AbbVieSynthroid | $100 | $1,36731 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,528 internal medicine providers in Louisiana.
Other internal medicine in Baker
- Ernest ThompsonBaker$2.1M
- William SmithNew Orleans$50.5M
- Robert JeanfreauMetairie$13.4M
- Katherine PearceBaton Rouge$12M
- Brian LewisNew Orleans$2M
- Otis BarnumNatchitoches$1.8M
- Satinder SainiCrowley$1.8M
- Randall MillerEunice$1.2M
- Donna RyanBaton Rouge$991K
- Steven DeitelzweigNew Orleans$939K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.